Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07949474
PHASE3

Semaglutide in Alcohol Use Disorder

Sponsor: University of Minnesota

View on ClinicalTrials.gov

Summary

This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.

Official title: A 45-week, Randomized, Controlled Trial of Semaglutide on Alcohol Related Outcomes in Adults With Alcohol Use Disorder and Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

128

Start Date

2027-05-01

Completion Date

2033-04-30

Last Updated

2026-11-19

Healthy Volunteers

No

Interventions

DRUG

Wegovy

Participants in this arm will receive 42 weeks of treatment with semaglutide

OTHER

Placebo

Participants in this arm will receive 42 weeks of placebo

Locations (1)

University of Minnesota Center for Pediatric Obesity Medicine

Minneapolis, Minnesota, United States